BACKGROUND: Acute myelogenous leukemia (AML) associated with core-binding-factor (CBF) abnormalities is the type of leukemia most responsive to cytarabine (ara-C) therapy and is of relative favorable prognosis. In vitro and ex vivo observations suggest that increases in intracellular ara-C levels influenced by administration of fludarabine and granulocyte colony-stimulating factor (GCSF) increase the effect of ara-C, prompting us to clinically evaluate the efficacy of such combinations. METHODS: We analyzed the event-free survival of patients with newly diagnosed CBF AML treated with fludarabine and ara-C (FA) (N = 45) or with FA and GCSF (FLAG) (N = 22) and compared results to patients treated with regimens consisting of idarubicin and ara-C with or without GCSF (IA/IAG) (N = 47). RESULTS: After accounting for prognostic covariates other than treatment (including year in which treatment was administered), FA, and in particular FLAG, were associated with longer event-free survival than IA/IAG. CONCLUSIONS: Thus, our data lends clinical credence to the observed modulation of ara-C by fludarabine and GCSF. (c) 2008 American Cancer Society
BACKGROUND:Acute myelogenous leukemia (AML) associated with core-binding-factor (CBF) abnormalities is the type of leukemia most responsive to cytarabine (ara-C) therapy and is of relative favorable prognosis. In vitro and ex vivo observations suggest that increases in intracellular ara-C levels influenced by administration of fludarabine and granulocyte colony-stimulating factor (GCSF) increase the effect of ara-C, prompting us to clinically evaluate the efficacy of such combinations. METHODS: We analyzed the event-free survival of patients with newly diagnosed CBF AML treated with fludarabine and ara-C (FA) (N = 45) or with FA and GCSF (FLAG) (N = 22) and compared results to patients treated with regimens consisting of idarubicin and ara-C with or without GCSF (IA/IAG) (N = 47). RESULTS: After accounting for prognostic covariates other than treatment (including year in which treatment was administered), FA, and in particular FLAG, were associated with longer event-free survival than IA/IAG. CONCLUSIONS: Thus, our data lends clinical credence to the observed modulation of ara-C by fludarabine and GCSF. (c) 2008 American Cancer Society
Authors: Frederick R Appelbaum; Kenneth J Kopecky; Martin S Tallman; Marilyn L Slovak; Holly M Gundacker; Haesook T Kim; Gordon W Dewald; Hagop M Kantarjian; Sherry R Pierce; Elihu H Estey Journal: Br J Haematol Date: 2006-08-25 Impact factor: 6.998
Authors: E H Estey; P F Thall; J E Cortes; F J Giles; S O'Brien; S A Pierce; X Wang; H M Kantarjian; M Beran Journal: Blood Date: 2001-12-15 Impact factor: 22.113
Authors: Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco Journal: J Clin Oncol Date: 2003-12-15 Impact factor: 44.544
Authors: R F Schlenk; A Benner; J Krauter; T Büchner; C Sauerland; G Ehninger; M Schaich; B Mohr; D Niederwieser; R Krahl; R Pasold; K Döhner; A Ganser; H Döhner; G Heil Journal: J Clin Oncol Date: 2004-08-02 Impact factor: 44.544
Authors: John C Byrd; Amy S Ruppert; Krzysztof Mrózek; Andrew J Carroll; Colin G Edwards; Diane C Arthur; Mark J Pettenati; Judith Stamberg; Prasad R K Koduru; Joseph O Moore; Robert J Mayer; Frederick R Davey; Richard A Larson; Clara D Bloomfield Journal: J Clin Oncol Date: 2004-03-15 Impact factor: 44.544
Authors: Roland B Walter; Frederick R Appelbaum; Martin S Tallman; Noel S Weiss; Richard A Larson; Elihu H Estey Journal: Blood Date: 2010-06-10 Impact factor: 22.113
Authors: David H Salinger; David K Blough; Paolo Vicini; Claudio Anasetti; Paul V O'Donnell; Brenda M Sandmaier; Jeannine S McCune Journal: Clin Cancer Res Date: 2009-08-11 Impact factor: 12.531